184 related articles for article (PubMed ID: 37189432)
1. Screening and Identification of a Prognostic Model of Ovarian Cancer by Combination of Transcriptomic and Proteomic Data.
Jiang J; Chen Z; Wang H; Wang Y; Zheng J; Guo Y; Jiang Y; Mo Z
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189432
[TBL] [Abstract][Full Text] [Related]
2. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
An Y; Yang Q
Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
[TBL] [Abstract][Full Text] [Related]
5. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
6. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
7. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
Song Y; Qu H
BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
[TBL] [Abstract][Full Text] [Related]
9. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
Li Q; Xiao X; Feng J; Yan R; Xi J
Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
[TBL] [Abstract][Full Text] [Related]
11. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
Wang J; Yan S; Chen X; Wang A; Han Z; Liu B; Shen H
Technol Cancer Res Treat; 2022; 21():15330338211035270. PubMed ID: 35538679
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
13. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
14. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
Zhou JG; Zhao HT; Jin SH; Tian X; Ma H
Gynecol Oncol; 2019 Dec; 155(3):499-507. PubMed ID: 31662204
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
[TBL] [Abstract][Full Text] [Related]
17. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
Cao T; Shen H
J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
[TBL] [Abstract][Full Text] [Related]
18. Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.
Li Y; Gong X; Hu T; Chen Y
BMC Cancer; 2022 Jan; 22(1):74. PubMed ID: 35039008
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]